Teresa Neeno, MD
Allergy & Immunology · Sacramento, CANPI 1366553273
Payments from drug & device makers
Across 323 payments — averaging $40.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Biocryst US Sales Co., LLC$1K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$892
- CSL Behring$732
- plus $5K from 22 others
What the payments were for
- Consulting fees$210%
- Food & beverage$13,103100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $2,860 |
| GSK | 35 | $1,319 |
| Biocryst US Sales Co., LLC | 17 | $1,272 |
| Sanofi | 31 | $1,238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $892 |
| CSL Behring | 29 | $732 |
| Regeneron Healthcare Solutions, Inc. | 20 | $728 |
| Teva Pharmaceuticals USA, Inc. | 10 | $679 |
| Amgen | 20 | $665 |
| Genentech USA, Inc. | 13 | $601 |
| Pharming Healthcare, Inc. | 8 | $493 |
| Grifols USA, LLC | 9 | $279 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $229 |
| Ionis Pharmaceuticals, Inc. | 5 | $228 |
| Novartis | 9 | $171 |
| Kaleo, Inc. | 4 | $130 |
| Genentech, Inc. | 1 | $125 |
| Shire North American Group Inc | 1 | $124 |
| Sanofi-aventis U.S. LLC | 1 | $87 |
| LEO Pharma Inc. | 4 | $83 |
| Optinose US, Inc. | 1 | $47 |
| Incyte Corporation | 1 | $28 |
| Octapharma USA, Inc. | 1 | $25 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| ADMA Biomanufacturing LLC | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Organon | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,132 in reported general payments places this provider in the 75th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 14 | $356,880 |
| XolairOmalizumab | 62 | $228,407 |
| TezspireTezepelumab-Ekko | 43 | $171,165 |
| NucalaMepolizumab | 15 | $143,385 |
| Dupixent SyringeDupilumab | 22 | $82,677 |
| FasenraBenralizumab | 11 | $66,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $51,078 |
| Spiriva RespimatTiotropium Bromide | 51 | $33,433 |
| SymbicortBudesonide/Formoterol Fumarate | 51 | $12,862 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,522 |
| AlvescoCiclesonide | 16 | $10,614 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $9,444 |
| DuleraMometasone/Formoterol | 14 | $8,868 |
| BreynaBudesonide/Formoterol Fumarate | 38 | $6,928 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $892 | $356,88014 claims |
| AstraZenecaTezspire, Fasenra, Symbicort, Breztri Aerosphere | $2,860 | $262,469122 claims |
| Genentech, Inc.Xolair | $125 | $228,40762 claims |
| GSKNucala, Trelegy Ellipta, Incruse Ellipta, Breo Ellipta | $1,319 | $210,785115 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $679 | $3,61913 claims |
| Hikma Pharmaceuticals USAEpinephrine | $24 | $2,15513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Sacramento
- Neil ParikhSacramento$136K
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
- Alan GoldsobelSan Jose$3.3M
- Steven WeinsteinHuntington Beach$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.